Search

Your search keyword '"Morin, F."' showing total 1,381 results

Search Constraints

Start Over You searched for: Author "Morin, F." Remove constraint Author: "Morin, F."
1,381 results on '"Morin, F."'

Search Results

3. Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer

6. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

7. Outpatient Management of Patients With COVID-19: Multicenter Prospective Validation of the Hospitalization or Outpatient Management of Patients With SARS-CoV-2 Infection Rule to Discharge Patients Safely

8. PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project

9. Surfaces and equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the emergency department at a university hospital

12. Osimertinib chez les patients atteint d’un cancer bronchique non à petites cellules (CBNPC) muté EGFR présentant des métastases cérébrales ou leptoméningées: résultats de l’étude IFCT-1804 ORBITAL

13. Traitement des cancers bronchiques à petites cellules (CBPC) : intérêt des études en vie réelle. À propos de 2 études de l’IFCT : IFCT-1905 Clinatezo et IFCT-2105 Lurbiclin

14. Essai randomisé contrôlé comparant l’association pembrolizumab plus chimiothérapie à la chimiothérapie seule dans le mésothéliome pleural avancé, non prétraité (essai IND. 227, IFCT-1901)

15. Efficacité et tolérance du sotarasib chez les patients porteurs d’un cancer bronchique non à petites cellules avec une mutation KRAS G12 C : résultats de l’étude en vie réelle IFCT-2102 Lung KG12Ci

16. Qu'attendent les médecins urgentistes français de moins de 35 ans dans leur pratique? Une enquête nationale de la commission jeunes de la société française de médecine d'urgence.

20. An EEG-Based Brain-Machine Interface to Control a 7-Degrees of Freedom Exoskeleton for Stroke Rehabilitation

21. Performances and limits of Bag-Valve-Device for pre-oxygenation and manual ventilation: A comparative bench and cadaver study

22. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program

25. Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial

26. Étude de phase II-III randomisée (IFCT-1701 DICIPLE), comparant une continuation du doublet d’immunothérapie nivolumab–ipilimumab jusqu’à progression à une observation chez des patients avec un cancer bronchique non à petites cellules (CBNPC) métastatique après un traitement d’induction de 6 mois par nivolumab–ipilimumab

27. Capmatinib chez les patients porteurs d’un cancer bronchique non à petites cellules avec une mutation MET exon 14 : résultats de l’étude en vraie vie IFCT-2104 CapmATU

29. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

35. 972O Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial

36. 1106P Capmatinib for METex14 non-small cell lung cancer patients: Results of the real-world study IFCT-2104 CapmATU

41. 1324P Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial

42. 1259MO Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): An open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF)

43. Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma

Catalog

Books, media, physical & digital resources